Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis
- Resource Type
- Source
- Leuk Lymphoma
- Subject
Oncology Cancer Research medicine.medical_specialty Immunoconjugates medicine.medical_treatment Subgroup analysis macromolecular substances Pembrolizumab Antibodies, Monoclonal, Humanized Transplantation, Autologous Article 03 medical and health sciences 0302 clinical medicine Autologous stem-cell transplantation Refractory immune system diseases hemic and lymphatic diseases Internal medicine polycyclic compounds Classical Hodgkin lymphoma medicine Humans Brentuximab vedotin Brentuximab Vedotin Salvage Therapy Chemotherapy business.industry Hematopoietic Stem Cell Transplantation food and beverages Hematology Hodgkin Disease 030220 oncology & carcinogenesis Pembrolizumab, hodgkin lymphoma, autologous stem cell transplantation, brentuximab vedotin Neoplasm Recurrence, Local business Chemoradiotherapy Stem Cell Transplantation 030215 immunology medicine.drug - Language
- English